Biomerica, Inc. Retains Merriman Capital as Capital Markets Advisor

GlobeNewswire Europe



SAN FRANCISCO - October 4, 2013 - Merriman Capital, Inc. ("Merriman"), a wholly owned subsidiary of Merriman Holdings, Inc. (MERR), announced today that it has been retained as Capital Markets Advisor to Biomerica, Inc. ("Biomerica") (BMRA). Merriman will provide issuer consulting and equity capital markets advisory services to Biomerica`s management team.
 
Merriman provides its capital markets clients with corporate brokerage services and advice on the effective engagement of a potentially broader institutional shareholder base, financing solutions, and strategies for organizing their capital structure. Merriman`s Capital Markets Advisory Group clients also benefit from access to unique capital solutions and the implementation of various public markets initiatives.
 
Biomerica develops and manufactures cost-effective, biomedical diagnostic products used at home, in physicians` offices and in hospital or clinical laboratories for detecting medical conditions and diseases. Biomerica primarily focuses on products for diabetes, gastrointestinal disease and esoteric testing. Biomerica`s headquarters is located in Irvine, California, with subsidiaries in Germany and Mexico.
 
"We are pleased to announce Biomerica as the newest addition to our growing portfolio of corporate clients," commented Doug Rogers, Managing Director and Head of the Capital Markets Advisory Group at Merriman. "Our corporate clients benefit from a range of services including market insight, corporate brokerage services as well as strategic advice for capital solutions."
 
About Merriman Capital, Inc.

Merriman Capital, Inc. is a corporate advisory-focused registered investment bank that provides equity and options execution services and differentiated research for high growth companies. The firm also provides capital formation, advisory, and M&A services. Merriman Capital, Inc. is a wholly owned subsidiary of Merriman Holdings, Inc. and is the leading investment banking firm for unique high-growth companies. For more information, please go to http://www.merrimanco.com.
 
Merriman Capital, Inc. is a registered broker-dealer and member of The Financial Industry Regulatory Authority (FINRA) http://www.finra.org/ and the Securities Investor Protection Corporation (SIPC) http://www.sipc.org/.
 
About Biomerica, Inc.

Biomerica, Inc. (www.biomerica.com) is a global biomedical company that develops, manufactures and markets advanced diagnostic products used at the point-of-care (in home and in physicians` offices ) and in hospital/clinical laboratories for the early detection of medical conditions and diseases. The Company`s products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focuses on products for Diabetes, Gastrointestinal Disease and esoteric testing.

Note to Investors

This press release contains certain forward-looking statements based on our current expectations, forecasts and assumptions that involve risks and uncertainties. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity. Forward-looking statements in this release are based on information available to us as of the date hereof. Our actual results may differ materially from those stated or implied in such forward-looking statements, due to risks and uncertainties associated with our business, which include the risk factors disclosed in our Form 10-K-A filed on April 30, 2013 and the Form 10-Q filed on August 14, 2013. Forward-looking statements include statements regarding our expectations, beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "should," and "would" or similar words. We assume no obligation to update the information included in this press release, whether as a result of new information, future events or otherwise. The Form 10-K-A filed on April 30, 2013 and the Form 10-Q filed on August 14, 2013, together with this press release and the financial information contained herein, are available on our website, www.merrimanco.com. Please click on "Investor Relations."
 

# # #

At Merriman:
 
Douglas Rogers
Managing Director
Merriman Capital, Inc.
(415) 248-5612
 
Will Febbo
Chief Operating Officer
Merriman Capital, Inc.
(415) 248-5603
 
Howard Bernstein
Chief Compliance Officer
Merriman Capital, Inc.
(415) 262-1377




This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Merriman Holdings Inc. via Thomson Reuters ONE

HUG#1733592

Rates

View Comments (0)